Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07604974 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess the Safety, Tolerability and Efficacy of ION775
A Phase 2 study, sponsored by Ionis Pharmaceuticals.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 72
- Enrollment target
NCT07604974 is a Phase 2 study that is actively recruiting participants, run by Ionis Pharmaceuticals. The registered enrollment target is 72 participants.
The verdict
NCT07604974, a Phase 2 study, is actively recruiting participants, sponsored by Ionis Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 72 participants
- Enrollment target
Study Summary
The main objective of this study is to evaluate the effect of ION775 on fasting triglyceride (TG) levels in participants with hypertriglyceridemia (HTG) and severe hypertriglyceridemia (sHTG).
Interventions
- DRUG ION775
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2026-05-12 |
| Est. Completion | 2028-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07604974
The ClinicalTrials.gov registry entry for NCT07604974 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ionis Pharmaceuticals, which has 76 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ION775 is the first listed.
NCT07604974 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07604974 about?
NCT07604974 is a clinical study titled "A Study to Assess the Safety, Tolerability and Efficacy of ION775". The main objective of this study is to evaluate the effect of ION775 on fasting triglyceride (TG) levels in participants with hypertriglyceridemia (HTG) and severe hypertriglyceridemia (sHTG).
What is the current status of trial NCT07604974?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 72 participants. The study started on 2026-05-12. Estimated completion is 2028-03.
What interventions are being tested in trial NCT07604974?
The interventions under investigation include: ION775 (DRUG).
Who is sponsoring clinical trial NCT07604974?
This trial is sponsored by Ionis Pharmaceuticals, which has 76 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.